Latest

GLP-1

·April 23, 2026·8 min read

GLP-1 Drugs Target the Roots of Dementia

A comprehensive review of 30 studies finds that GLP-1 receptor agonists are effective at tackling the biological drivers of Alzheimer’s disease.

Featured Genetics Neuroscience

·April 8, 2026·8 min read

Ozempic Weight Loss Success Varies by DNA

A new study of 28,000 people identifies genetic markers in the GLP1R and GIPR genes that explain why some patients lose more weight or experience more nausea on GLP-1 drugs.

Featured Neuroscience

·March 10, 2026·13 min read

Why GLP-1 Drugs Affect Men and Women Differently

A new atlas reveals that GLP-1—the backbone of blockbuster weight-loss drugs—is mapped differently in the male and female brain.

This shows a woman holding her head in pain.

Featured Neurology Neuroscience

·March 2, 2026·7 min read

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Unexpected relief. New research shows that patients taking GLP-1 drugs for diabetes or weight loss also experience fewer emergency room visits and need fewer medications for their chronic migraines.

This shows a brain surrounded by faded foods, as though the foods represent distant memories.

Featured Neuroscience

·February 12, 2026·7 min read

Memory of Food: Brain Circuits Control Appetite Through Context

Forget the "willpower" myth, new research suggests that your past experiences are the real secret to appetite control. By identifying a hidden circuit that links memory to hunger, scientists have discovered how the brain uses your environment to decide when it's time to eat, and how a "glitch" in this system leads to overeating.

This shows a person holding their head in pain.

Featured Neurology Neuroscience

·June 24, 2025·3 min read

GLP-1 Drug Cuts Migraine Days in Half

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and chronic migraine. Participants reported an average of 11 fewer headache days per month, alongside improved disability scores and quality of life.

Featured Neuroscience

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.

Featured Neuroscience

·May 13, 2025·6 min read

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Trial

In a 72-week clinical trial, tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy), with participants losing an average of 20.2% of their body weight versus 13.7%. The study directly compared the two drugs at their highest doses in people with obesity but without diabetes.

Featured Neuroscience Psychology

·April 18, 2025·5 min read

Potential Depression Risk Linked to Ozempic-Like Drugs

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and increased risk of depression and suicidal ideation, especially in people with low dopamine function. Researchers used advanced pharmacogenomic tools to identify genetic pathways that may be vulnerable to dopamine dysregulation when exposed to these medications.

Featured Neurology Neuroscience

·April 16, 2025·5 min read

Ozempic Linked to Lower Alzheimer’s Risk

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias. Researchers analyzed Medicare data and found that patients taking these drugs had significantly lower rates of cognitive decline compared to those using other glucose-lowering medications.

This shows the outline of a person and a brain.

Featured Neuroscience

·January 20, 2025·6 min read

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits, including reduced risks of addiction, Alzheimer’s, and dementia. However, they also pose risks for pancreatitis and kidney conditions, emphasizing the need for careful monitoring.

Featured Neuroscience Psychology

·September 4, 2024·5 min read

No Link Found Between Ozempic and Suicide Risk

A new study has found no evidence that GLP-1 analogues, common diabetes drugs, increase the risk of suicide, self-harm, or related mental health issues. Researchers analyzed data from around 300,000 people treated with these medications and found no clear link between the drugs and mental health risks.

1 2

GLP-1

GLP-1 Drugs Target the Roots of Dementia

Ozempic Weight Loss Success Varies by DNA

Why GLP-1 Drugs Affect Men and Women Differently

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Memory of Food: Brain Circuits Control Appetite Through Context

GLP-1 Drug Cuts Migraine Days in Half

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Trial

Potential Depression Risk Linked to Ozempic-Like Drugs

Ozempic Linked to Lower Alzheimer’s Risk

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

No Link Found Between Ozempic and Suicide Risk

Astrocytes Identified as Key Target for Treating Fragile X Syndrome

Liver Talks to the Brain to Control Appetite

Rethinking Vibration as an Emotional Language

Immature Neurons and the Secret to Alzheimer’s Resilience

Subscribe